Abstract
Objectives Whole SARS-CoV-2 genome sequencing from COVID-19 patients is useful for infection control and regional trends evaluation. We report a lineage data collected from hospitals in the Kanto region of Japan.
Methods We performed whole genome sequencing in specimens of 198 COVID-19 patients at 13 collaborating hospitals in the Kanto region. Phylogenetic analysis and fingerprinting of the nucleotide substitutions underwent to differentiate and classify the viral lineages.
Results More than 90% of the strains belonged to Clade 20B and two lineages (B.1.1.284 and B.1.1.214) have been detected predominantly in the Kanto region. However, one sample from a COVID-19 patient in November 2020, belonged to the B.1.346 lineage of Clade 20C, which has been prevalent in western United States. The patient had no history of overseas travel and no contact with anyone who had travelled abroad, suggesting that this strain appeared likely to have been imported from western United States, across the strict quarantine barrier.
Conclusion B.1.1.284 and B.1.1.214 have been identified predominantly in the Kanto region and B.1.346 of clade 20C in one patient was probably imported from western United States. These results illustrate that a decentralized network of hospitals can be significantly advantageous for monitoring regional molecular epidemiologic trends.
Highlights
· Whole SARS-CoV-2 genome sequencing is useful for infection control
· B.1.1.284 and B.1.1.214 have been identified predominantly in the Kanto region
· B.1.346 of Clade 20C was detected in one COVID-19 patient in November
· Molecular genomic data sharing provides benefits to public health against COVID-19
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding sources of Keio Gijuku Academic Development Funds and the Japan Agency for Medical Research Development (AMED JP20he0622043, K.K. as the Lead) were used for costs of consumables and deep sequencing of viral genome. The costs of consumables were supported in part by Ryoshoku-Kenkyu-kai which aimed to tackle infections disease control (M.S.). The design and data analyses of this study were performed independently of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board of Keio University School of Medicine (approval number: 20200062) with each collaborating hospitals review board and was conducted according to the principles of the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data sharing We downloaded the full nucleotide sequences of the SARS-CoV-2 genomes from the GISAID database (https://www.gisaid.org/). A table of the contributors is available (acknowledgment table). We have uploaded the full nucleotide sequences of our cohort to the GISAID database.
